Skip to main content

Table 3 Characteristics of 100 ICU patients receiving intravenous (IV) cefepime

From: Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy

 

Cefepime neurotoxicity

Rest of cohort

P value

n = 15

n = 85

Age, years, mean

69

66

0.16

Male gender, n (%)

11 (73)

50 (59)

0.39

Acute kidney injury, n (%)

13 (87)

64 (75)

0.51

Chronic kidney disease, n (%)

10 (67)

30 (35)

0.042

Hemodialysis, n (%)

4 (27)

28 (33)

0.77

Peak creatinine, median (IQR)

2.8 (1.7-3.1)*

2.3 (1.5-3)

0.36

Nadir eGFR, median (IQR)

22.5 (20.8-34.3)

27.5 (18-45)

0.53

Mean daily cefepime dose, g, median (IQR)

2.5 (1.7-4)*

2.5 (2-3.5)

0.66

Cefepime duration, days, median (IQR)

5 (4.8-7.3)*

7 (4-10)

0.26

Appropriate dose reduction for renal function, n (%)

4 (29)*

64 (75)

0.001

  1. *Data available for 14 of the 15 cases of cefepime neurotoxicity. IQR, interquartile range; g, grams.